Related Experiment Video
Updated: Jun 14, 2026
14:51
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Epigenetic mechanisms in AML - a target for therapy
Yasuhiro Oki1, Jean-Pierre J Issa
1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cancer Treatment and Research
|March 23, 2010
Summary
Epigenetic changes like DNA methylation are crucial in acute myelogenous leukemia (AML) development. Epigenetic therapy offers a promising approach to reverse gene silencing and treat AML.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Epigenetics involves gene regulation without altering DNA sequence, including DNA methylation and histone modifications.
- Aberrant epigenetic mechanisms, particularly DNA methylation and histone deacetylation, contribute to leukemogenesis by silencing critical genes.
- These epigenetic alterations are frequently observed in acute myelogenous leukemia (AML), impacting gene function.
Purpose of the Study:
- To highlight the significant role of epigenetic changes in AML development and progression.
- To introduce epigenetic therapy as a targeted treatment strategy for AML.
- To review the safety and efficacy of current epigenetic therapies in clinical settings.
Main Methods:
- The study reviews existing literature on epigenetic mechanisms in AML.
- It focuses on DNA methylation and histone tail modifications as key epigenetic alterations.
- Analysis of gene silencing in AML through aberrant epigenetic events is discussed.
Main Results:
- Abnormal DNA methylation affects multiple genes in AML (e.g., p15, p73, E-cadherin).
- Altered histone-modifying enzyme activity is observed in AML, often due to chromosomal translocations.
- Epigenetic changes are integral to AML pathogenesis.
Conclusions:
- Epigenetic modifications are critical drivers in AML.
- Targeting epigenetic pathways offers a viable therapeutic strategy.
- Epigenetic therapies have demonstrated safety and efficacy in clinical studies for AML.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:37Epigenetic Regulation
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...